KLHL17作为宫癌的预后指标和治疗目标:全面分析
Guizhen Lyu1, Jinyuan Li2, Dongbing Li3
1Dongguan Key Laboratory of Clinical Medical Test Diagnostic Technology for Oncology, Dongguan Labway Clinical Laboratory Co., Ltd., Dongguan 523429, Guangdong, China.
Combinatorial chemistry & high throughput screening
|May 15, 2025
概括
凯尔奇样家族成员17 (KLHL17) 在宫癌 (CESC) 中表达不规则,并与较差的生存率有关. 这项研究确定了KLHL17作为预后标志物和CESC的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 生物信息学是一种生物信息学.
- 分子生物学分子生物学
背景情况:
- 类家族成员17 (KLHL17) 在宫癌 (CESC) 中的作用尚不清楚.
- 了解KLHL17的功能对于开发新型治疗策略至关重要.
研究的目的:
- 通过生物信息学和实验验证,阐明KLHL17在CESC中的作用.
- 在CESC中评估KLHL17作为预后生物标志物和潜在的治疗标.
主要方法:
- 利用TCGA数据库用于CESC和其他癌症中的KLHL17表达分析.
- 研究了与临床特征,免疫细胞透和治疗疗效的相关性.
- 使用qRT-PCR和单细胞测序数据验证了KLHL17表达.
主要成果:
- KLHL17在不同癌症中表现不规则,CESC的高水平与无进展生存率的降低相关.
- KLHL17表达是CESC患者的显著预后指标.
- KLHL17与免疫细胞透,免疫检查点基因,MSI状态和药物敏感性相关.
结论:
- 在CESC中,KLHL17作为一个有价值的预后标记.
- KLHL17代表了宫癌治疗的潜在治疗标.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K